The pathophysiological mechanisms that induce the repression of SLAMF3 in HCC cells remain unknown, and additional studies are needed to identify the molecular partners of SLAMF3 to elucidate the mechanisms implicated in its tumor-suppressing functions. Here, LY9 is linked to hepatocellular carcinoma.